| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.6美元,归母净利润-2693.26万美元,同比去年增长9.19%
|
| 2025-11-13 |
财报披露：
美东时间 2025-11-13 盘前发布财报
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本5276.65万股
变动原因 ▼▲
- 原因：
- Common Stock offered 5,741,000 shares by the company
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.41美元,归母净利润-1792.32万美元,同比去年增长5.33%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.21美元,归母净利润-848.9万美元,同比去年增长19.94%
|
| 2025-04-29 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect two Class A directors of the Company, Stephen Glover and Gregory Freitag, J.D., C.P.A., each to hold office until the 2028 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified;
2.To approve an amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan;
3.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
4.To approve, by non-binding, advisory vote, the compensation of our named executive officers;
5.To conduct any other business properly brought before the Annual Meeting or any adjournment thereof.
|
| 2025-03-27 |
详情>>
业绩披露：
2024年年报每股收益-1.03美元,归母净利润-3761.04万美元,同比去年增长12.42%
|
| 2025-02-28 |
详情>>
内部人交易：
Freitag Gregory Gene等共交易2笔
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.82美元,归母净利润-2965.8万美元,同比去年增长7.45%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.53美元,归母净利润-1893.14万美元,同比去年增长10.68%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.3美元,归母净利润-1060.35万美元,同比去年增长-9.77%
|
| 2024-04-29 |
股东大会：
将于2024-06-24召开股东大会
会议内容 ▼▲
- 1.To elect two Class C directors of the Company, Frank Bedu-Addo, Ph.D. and Otis Brawley, M.D., each to hold office until the 2027 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified;
2.To approve an amendment to our Eighth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 75,000,000 shares to 150,000,000 shares;
3.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To approve, by non-binding, advisory vote, the compensation of our named executive officers;
5.To conduct any other business properly brought before the Annual Meeting or any adjournment thereof.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-1.39美元,归母净利润-4294.22万美元,同比去年增长-5.11%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.04美元,归母净利润-3204.4万美元,同比去年增长-47.55%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.69美元,归母净利润-2119.48万美元,同比去年增长-48.29%
|
| 2023-06-06 |
复牌提示：
2023-06-05 12:07:42 停牌，复牌日期 2023-06-05 12:12:42
|
| 2023-06-02 |
股东大会：
将于2023-07-14召开股东大会
会议内容 ▼▲
- 1.To elect two Class B directors of the Company, Kamil Ali-Jackson and Ilian Iliev, each to hold office until the 2026 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified;
2.To approve the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, which was approved by our Board of Directors on May 19, 2023;
3.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
4.To approve, by non-binding, advisory vote, the compensation of our named executive officers;
5.To conduct any other business properly brought before the Annual Meeting or any adjournment thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.To elect three Class A directors of the Company, Stephen Glover, Gregory Freitag and Sir Richard Sykes, each to hold office until the 2025 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To approve, by non-binding, advisory vote, the compensation of our named executive officers.
4.To conduct any other business properly brought before the Annual Meeting or any adjournment thereof.
|
| 2021-12-16 |
股东大会：
将于2022-01-19召开股东大会
会议内容 ▼▲
- 1.To ratify the prior approval of the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Plan Ratification Proposal”), which was adopted at the Company’s 2021 annual meeting of stockholders (the “2021 Annual Meeting of Stockholders”);
2.To conduct any other business properly brought before the Special Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.To elect two Class C directors of the Company, Frank Bedu-Addo, Ph.D. and Otis Brawley, M.D., to hold office until the 2024 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To approve the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, which was approved by our Board of Directors on December 8, 2020;
4.To approve, by non-binding advisory vote, the compensation of our named executive officers;
5.To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers;
6.To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in this “Proxy Statement.”
|
| 2020-04-29 |
股东大会：
将于2020-06-23召开股东大会
会议内容 ▼▲
- 1.To elect two Class B directors of the Company, Kamil Ali-Jackson, Esq. and Ilian Iliev, Ph.D., to hold office until the 2023 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
3.To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in this “Proxy Statement.”
|
| 2019-08-16 |
股东大会：
将于2019-09-24召开股东大会
会议内容 ▼▲
- 1.To elect three Class A directors of the Company, Gregory Freitag, Stephen Glover and Sir Richard Sykes, to hold office until the 2022 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
3.To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in this “Proxy Statement.”
|
| 2019-03-18 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2018-04-25 |
股东大会：
将于2018-06-19召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ nominees, Sol Barer, Ph.D. and Brian Leuthner, to hold office until the 2021 Annual Meeting of Stockholders.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in this “Proxy Statement.”
|
| 2017-04-28 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ nominees, Isaac Blech, James Loughlin and R. Loch Macdonald, M.D., Ph.D., to hold office until the 2020 Annual Meeting of Stockholders.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in this ‘‘Proxy Statement.’’
|
| 2016-04-28 |
股东大会：
将于2016-06-21召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ nominees, Kurt Conti, Liam Ratcliffe, M.D., Ph.D., and Robert Spiegel, M.D., to hold office until the 2019 Annual Meeting of Stockholders.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To conduct any other business properly brought before the Annual Meeting.
|